United States Federal Circuit

ResetAA Font size: Print

Impax Lab. Inc. v. Lannett Holdings Inc, 17-2020

Affirmed the ruling that certain patent claims for pharmaceutical formulations, intranasal administration devices or aqueous solutions of zolmitripatan are not valid. The court found that defendant failed to prove that the claims at issue would have been obvious over the prior art.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2018/06/28


  • Lourie


  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More